К. Б. Мирзаев

511 total citations
89 papers, 299 citations indexed

About

К. Б. Мирзаев is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Infectious Diseases. According to data from OpenAlex, К. Б. Мирзаев has authored 89 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Cardiology and Cardiovascular Medicine, 26 papers in Pharmacology and 18 papers in Infectious Diseases. Recurrent topics in К. Б. Мирзаев's work include Antiplatelet Therapy and Cardiovascular Diseases (25 papers), Pharmacogenetics and Drug Metabolism (19 papers) and Atrial Fibrillation Management and Outcomes (15 papers). К. Б. Мирзаев is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (25 papers), Pharmacogenetics and Drug Metabolism (19 papers) and Atrial Fibrillation Management and Outcomes (15 papers). К. Б. Мирзаев collaborates with scholars based in Russia, Norway and Bangladesh. К. Б. Мирзаев's co-authors include Д. А. Сычев, Kristina Ryzhikova, Е. А. Гришина, Д. А. Андреев, G. V. Rаmenskаya, Tanya Bogoslovsky, Tatiana Shelekhova, Irina V. Bure, О. Л. Барбараш and V. I. Ganyukov and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Clinical Pharmacology and Clinical Therapeutics.

In The Last Decade

К. Б. Мирзаев

66 papers receiving 287 citations

Peers

Countries citing papers authored by К. Б. Мирзаев

Since Specialization

Citations

This map shows the geographic impact of К. Б. Мирзаев's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by К. Б. Мирзаев with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites К. Б. Мирзаев more than expected).

Fields of papers citing papers by К. Б. Мирзаев

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by К. Б. Мирзаев. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by К. Б. Мирзаев. The network helps show where К. Б. Мирзаев may publish in the future.

Co-authorship network of co-authors of К. Б. Мирзаев

This figure shows the co-authorship network connecting the top 25 collaborators of К. Б. Мирзаев. A scholar is included among the top collaborators of К. Б. Мирзаев based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with К. Б. Мирзаев. К. Б. Мирзаев is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Laboratory Evaluation of the Platelet Component of Hemostasis in acute Coronary Syndrome With ST Segment Elevation 2025 ·Russian Sklifosovsky Journal Emergency Medical Care ·(unknown), (unknown), Д. А. Сычев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown)	0
2	Cytochrome СYP2C19 gene polymorphisms and bleeding in patients treated with clopidogrel as part of dual antithrombotic therapy after acute coronary syndrome 2024 ·А. И. Кочетков, (unknown), (unknown), (unknown), (unknown), (unknown), О. Д. Остроумова, К. Б. Мирзаев, Д. А. Сычев	0
3	Clinical and pharmacogenetic features of patients with upper gastrointestinal lesions at a multidisciplinary hospital: the role of nonsteroidal anti-inflammatory drugs 2024 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), О. В. Аверков, (unknown), К. Б. Мирзаев, Д. А. Сычев	1
4	Patients’ Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), К. Б. Мирзаев, Д. А. Сычев	1
5	Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown), Anastasiya V. Petrova, (unknown), (unknown), Д. А. Сычев	0
6	Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients 2023 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Irina V. Bure, Ametov As, I V Poddubnaya, К. Б. Мирзаев, Д. А. Сычев	1
7	Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study 2023 ·Pharmacy & Pharmacology ·(unknown), (unknown), (unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown), (unknown), (unknown), О. В. Аверков, Д. А. Сычев	0
8	Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients 2023 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Irina V. Bure, Ametov As, I V Poddubnaya, К. Б. Мирзаев, Д. А. Сычев	0
9	Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients 2023 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), К. Б. Мирзаев, Д. А. Сычев	1
10	Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), О. В. Аверков, (unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown), Д. А. Сычев	0
11	Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Irina V. Bure, (unknown), (unknown), К. Б. Мирзаев, Ametov As, I V Poddubnaya, Д. А. Сычев	2
12	The Effect of Carriage of <i>CYP3A53</i> and <i>CYP3A422</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown), (unknown), (unknown), (unknown), О. В. Аверков, Д. А. Сычев	0
13	Potential factors of Helicobacter pylori resistance to clarithromycin 2022 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Н. Б. Лазарева, (unknown), М. В. Журавлева, (unknown), (unknown), (unknown), К. Б. Мирзаев, (unknown), (unknown)	1
14	CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study 2022 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), (unknown), Д. А. Сычев, (unknown), (unknown), Е. А. Гришина, К. Б. Мирзаев, (unknown), Владимир Петрович Фисенко	6
15	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring 2021 ·Drug Metabolism and Personalized Therapy ·(unknown), Irina V. Bure, (unknown), (unknown), К. Б. Мирзаев, (unknown), О. Д. Остроумова, Smirnov Vv, Е. А. Гришина, (unknown), (unknown), Д. А. Сычев	3
16	Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation 2020 ·SHILAP Revista de lepidopterología ·К. Б. Мирзаев, (unknown), (unknown), (unknown), (unknown), (unknown), Е. А. Гришина, (unknown), (unknown), (unknown), (unknown), Л. З. Болиева, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Д. А. Сычев	1
17	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia) 2018 ·Drug Metabolism and Personalized Therapy ·(unknown), К. Б. Мирзаев, (unknown), (unknown), (unknown), Н. Р. Максимова, (unknown), (unknown), (unknown), (unknown)	5
18	The ABCB1 , CYP2C19 , CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes 2018 ·Drug Metabolism and Personalized Therapy ·К. Б. Мирзаев, (unknown), Kristina Ryzhikova, Е. А. Гришина, (unknown), (unknown), (unknown), (unknown), (unknown), Д. А. Андреев, (unknown)	6
19	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 2015 ·SHILAP Revista de lepidopterología ·К. Б. Мирзаев, (unknown), (unknown), Д. А. Андреев, Д. А. Сычев	0
20	GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA 2015 ·SHILAP Revista de lepidopterología ·К. Б. Мирзаев, Д. А. Сычев, Д. А. Андреев	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact